iRhythm Holdings, Inc. (IRTC) SEC Filings & Earnings Calls

Integration risk and potential failure to realize anticipated synergies.

“challenges in integrating VitalConnect and realizing anticipated benefits and synergies on the expected timeline or at all” · word for word

Acquisition subject to customary closing conditions; may not close as anticipated.

“subject to the satisfaction or waiver of customary closing conditions.” · word for word

Medicare Reimbursement Dependency

“During the three and six months ended June 30, 2026, we received approximately 26% of our total revenue from the Medicare program through the Centers for Medicare & Medicaid Services ("CMS").” · word for word

FDA Enforcement Action

“Our May 25, 2023 receipt of a warning letter from FDA alleging non-conformities to regulations for medical devices, including medical device reporting requirements, relating to our Zio AT and medical device quality system requirements.” · word for word

Competitive Market Pressure

“Our iRhythm Services compete with a variety of products and services that provide alternatives for remote cardiac monitoring, including traditional, short-term Holter monitors and event monitors.” · word for word

Acquisition subject to regulatory approvals (HSR) and stockholder approval; integration risk; potential termination fee.

“Subject to receipt of Target stockholder approval and expiration or termination of HSR waiting period.”

Litigation resolved; $50M cash outflow; ongoing covenant not to sue for 6 years.

“Settlement payment of $50M; covenant not to sue for six years.”

Data breach may lead to regulatory fines, litigation, and reputational damage despite insurance coverage.

“Incident deemed material due to volume of potentially affected data; insurance may not cover all losses.”

Litigation settlement reduces uncertainty but $45M payment may impact cash flow; insurance coverage mitigates but exhausts policy limits.

“settlement payment of $45 million ... after which there will be no amounts remaining available ... under the policies” · word for word

Patent Litigation Risk

“Intellectual property litigation costs relating to our ongoing litigation with Welch-Allyn and BardyDx, wholly-owned subsidiaries of Baxter, during the three months ended March 31, 2026 were $3.7 million, as compared to $0.8 million for the three months ended March 31, 2025.” · word for word

Regulatory Risk (FDA Warning Letter)

“Our May 25, 2023 receipt of a warning letter from FDA alleging non-conformities to regulations for medical devices, including medical device reporting requirements, relating to our Zio AT and medical device quality system requirements.” · word for word

Reimbursement Risk

“If CMS or any of our key commercial payors reduce reimbursement rates for our iRhythm Services, our business, operating results, and prospects would be adversely affected.” · word for word

Credit Loss Risk

“Provision for credit losses increased to $10.4M from $8.9M in the prior year period.”

Supply Chain Risk

“The Company relies on single-source vendors to supply some of its disposable housings, instruments and other materials used to manufacture the Zio patches and the adhesive that binds the Zio patch to a patient’s body.” · word for word

Litigation-related expenses impacting operating costs

“litigation-related expenses” · word for word

Regulatory Compliance Risk

“Ongoing remediation for FDA observations and warning letter, along with other regulatory agencies” · word for word

Cybersecurity Risk

“Cybersecurity risks, including those involving network security breaches, services interruptions and other incidents affecting the confidentiality, integrity or availability of our data and systems, could result in the compromise of confidential data or critical systems” · word for word

Competition and Talent Retention Risk

“Competition for talent in our industry is intense.” · word for word

Reimbursement Risk

“Navigated CMS reimbursement challenges in long-term continuous monitoring” · word for word

Auditor change may signal increased scrutiny or internal control concerns, though no disagreements reported.

“No disagreements or reportable events; change appears routine.”

Regulatory compliance risk (FDA, EU MDR, UKCA)

“Failure to comply with applicable regulatory requirements can result in enforcement action by FDA, which may include any of the following sanctions: warning letters, fines, injunctions, consent decrees, and civil penalties.” · word for word

Reimbursement and pricing risk

“federal surprise billing laws that impose limits on amounts that can be charged to such patients and/or the amount we can receive for out-of-network services from commercial payors.” · word for word

Privacy and security regulation risk

“We are subject to risks related to privacy and security regulation.” · word for word

Net loss persists, though significantly reduced from prior year.

“Net loss of $5.2 million vs $46.2 million prior year”

Dependence on continued adoption of Zio services and market penetration.

“Growth driven by core accounts and new channel partnerships”

FDA Warning Letter and Ongoing Remediation

“Our receipt of Form 483 observations in August 2022 alleging certain quality system deficiencies... Our May 25, 2023 receipt of a warning letter from FDA alleging non-conformities to regulations for medical devices... Our receipt of 483 observations following July 2024 FDA inspections... we continue to work with FDA to resolve the issues identified.” · word for word

Patent Litigation Exposure

“On February 20, 2024, Welch Allyn, Inc. filed a complaint against the Company... alleging that the Company's Zio devices infringe certain of Welch Allyn's patents... On December 10, 2024, Bardy Diagnostics, Inc. filed a lawsuit against the Company... alleging that the Company's Zio Monitor patch infringes one of its patents.” · word for word

DOJ Investigation

“On March 26, 2021, the Company received a grand jury subpoena from the U.S. Attorney’s Office for the Northern District of California... On April 4, 2023, the Company received a Subpoena Duces Tecum from the Consumer Protection Branch, Civil Division of the U.S. Department of Justice... The Company is cooperating fully on these matters.” · word for word

Securities Class Action Lawsuit

“On February 6, 2024, a putative class action lawsuit was filed... alleging that the Company and its current Chief Executive Officer... violated Sections 10(b) and 20(a) of the Exchange Act... The case is now in discovery.” · word for word

Reimbursement Rate Risk

“CMS updates the reimbursement rates for diagnostic tests performed by IDTFs annually via the Medicare Physician Fee Schedule... the rate for CPT code 93229 experienced a decrease as compared to calendar year 2024... there is a continuing risk that relative value units assigned, and reimbursement rates set, by CMS may not adequately reflect the value and expe” · word for word